CSDDD Omnibus Explained – Practical interpretation (Pharma) Scenerio -2
Where the API supplier sits under CSDDD Key point: The API manufacturer in India/China is a: Direct business partner (Tier 1) Even though geographically outside the EU. Why this is
CSDDD Omnibus Explained – Practical interpretation (Pharma) Scenerio -1
Case: EU MAH → CMO (India) → API supplier (India) Under Omnibus CSDDD: Tier Entity Legal CSDDD Expectation Practical Pharma Reality Tier 0 EU MAH ✔ Fully in scope under the C
CSDDD Omnibus Explained
The Directive requires companies to identify, prevent, mitigate, and remediate: Environmental (E) impacts Social / Human Rights (S) impacts These are grounded in international stan
What truly defines a “Successful” Manager?
In the evolving landscape of leadership, we often debate what makes a manager truly effective. Is it deep technical expertise? Is it soft skills? Or is it something else entirely
FDA Warning Letter to Abbott Diabetes Care — Key Quality System Failures
Recently the U.S. Food and Drug Administration issued a Warning Letter to Abbott Diabetes Care following a routine inspection of their Alameda, CA facility that raised serious Qual
FDA Form 483 Deep Dive: Sterile Manufacturing Under the Microscope.
The U.S. Food and Drug Administration (FDA) issued a Form 483 to Eugia Pharma Specialities Limited, Sangareddy, Telangana, 502307 India following a January–February 2026 inspect
The True Cost of Non-Compliant Promotion of Medicinal Products…
Recent years have provided stark reminders of the financial, regulatory, and societal consequences of failures in pharmaceutical compliance and governance. 🔶 One widely cited ex
A comprehensive summary of the FDA Form 483 issued to Aurobindo Pharma Limited,
Unit VII (Inspection dated Jan 28 – Feb 10 2026), including what went wrong at the quality system level — root causes, system failures, and broader quality-management insights
Why “Precision” Isn’t Enough for the FDA: A Lesson in Method Equivalency.
I’ve been diving deep into a specific FDA 483 observation recently that every Analytical Lead and QA Manager should keep on their radar. It highlights a common trap: confusing
Regulatory Enforcement Alert — FDA Cracks Down on Misleading Claims in GLP-1 & Compounded Drug Marketing.
The pharmaceutical and compounding landscape is witnessing a significant regulatory shift.The U.S. Food and Drug Administration (FDA) is actively enforcing federal drug marketing a